TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Hemidiaphragmatic Paralysis With Diluted Continuous Interscalene Plexus Infusions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 80 years~* American Society of Anesthesiologists classification 1-3~* body mass index between 20 and 35~Exclusion Criteria:~* adults who are unable to give their own consent~* pre-existing neuropathy (assessed by history and physical examination)~* coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or prothrombin time ≥ 50)~* renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)~* hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)~* allergy to local anesthetics (LAs)~* pregnancy~* prior surgery in the ipsilateral neck region~* chronic pain conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Patients with two or more keloids on the trunk, upper extremities or thighs. The keloids must meet specified size criteria and have been present for greater than or equal to 1 year, been stable in size and symptoms for at least 6 months.~Exclusion Criteria:~* Use of other investigational drugs at the time of enrollment, or history of hypersensitivity to any of the study drugs or to drugs of similar chemical classes (e.g. lidocaine, epinephrine, and topical antibiotics as bacitracin and neomycin).~* History of repeated recurrence of keloid after prior surgical removal (4-5 times removed).~* Keloids near the hands, joints, and anogenital areas as recurrence might cause significant problems.~* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the patient in case of participation in the study~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- QAX576 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Weight Loss Intervention in College-age Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females age 18-25years~* Body Mass Index 25.0 to 29.9 kg/m2 (overweight)~* Agree to receive frequent contacts from investigators and communicate with program staff for up to 6 months~* Willing to measure blood glucose via finger prick test three to eight times per day for two weeks~* Able to give written informed consent~* Able to comply with study procedures~Exclusion Criteria:~* Unable or unwilling to give informed consent~* Travel plans that do not permit participation~* Pregnant or planning on becoming pregnant during the 6 months of participation in the study~* Weight loss or gain exceeding 5% of body weight in the past 3 months~* Current participation in a weight loss program~* Diagnosis of mental disorder or chronic disease~* History of eating disorder such as anorexia nervosa, bulimia nervosa, or binge eating disorder (unless approved by program staff)~* History of surgery or procedure that could affect swallowing or digestion~* Any person who is on a medically prescribed diet~* Any current supplement use other than a daily multivitamin~* Any current metabolic medication use other than birth control~* Any bleeding disorders or blood clotting problems~* Anyone who has donated blood or plasma in the last 20 days~* Any tobacco or illicit drug users~* Anyone who has allergies to any of the components of the liquid meal

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Counseling (Type: EXPERIMENTAL): Receive counseling for 8-wks
- Control (Type: PLACEBO_COMPARATOR): Does not receive counseling for 8-wks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Randomized Controlled Trial to Reduce Salt Intake Among Hypertensive Young Adults in Hong Kong

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* i) adults aged 18 to 44~* ii) diagnosed hypertension or borderline hypertension~* iii) complete collection of 24-hour urine at baseline~* iv) 24-hour urinary sodium excretion above 2000mg at baseline~* v) can communicate in Cantonese~Exclusion Criteria:~* i) renal illnesses;~* ii) taking diuretics;~* iii) taking RAS blockers;~* iv) attending or planning to attend new hypertension education programme or salt intake reduction programme during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Four-week weekly intervention to reduce salt intake.
- Control group (Type: OTHER): Usual government pamphlets.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Gamma Probe Localization of the Ureter

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Agrees to informed consent.~* Patients undergoing elective, open, abdominal surgery~* 18 years or older~* Normal renal function defined by a serum creatinine less than 1.5mg/dL~Exclusion Criteria:~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Does Hormonal Luteal Support After Intra-uterine Insemination (IUI) Increase the Pregnancy Rate?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Tubal patency demonstrated~* ovulation induction with human menopausal gonadotropin~Exclusion Criteria:~* ovulation induction with clomiphene citrate

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 43 Years
- Healthy Volunteers: t

Study Arms:
- control (Type: NO_INTERVENTION): None
- utrogestan (Type: EXPERIMENTAL): daily use of vaginal progesterone capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have symptomatic multiple myeloma requiring treatment~* Patients must have been approved for single or tandem autologous transplant~* Patients must be \> or = 65 years of age or diagnosed with renal insufficiency, defined as having a creatinine \> 3 mg/dl or a creatinine clearance \< 30 ml/minute~* Patients must not have a history of chronic obstructive or chronic restrictive pulmonary disease. Patients must have adequate pulmonary function studies \> 50% of predicted on mechanical aspects (FEV1, FVC, etc) and diffusion capacity (DLCO) \> 50% of predicted,~* Patients must have an ECHO or MUGA performed within 60 days prior to registration, LVEF \> 40%.~* Bilirubin, SGOT, SGPT must be less than 1.5 times the upper limit of normal~* Patients must have evaluable myeloma marker for response such as: \*Serum M protein \>1g/dl or urine M protein \>1g/24 hours and/or; \*Bone marrow plasmacytosis with \>20% plasma cells and/or; \*Extramedullary plasmacytosis; \*MRI/PET scan has focal lesions due to myeloma.~* Patients must be able to receive full doses of DT-PACE, in the opinion of the treating investigator, with the exception of cisplatin.~* Patients must have a performance status of 0-2 based on SWOG criteria unless the patient's status is due to active myeloma~* All patients must be informed of the investigational nature of the study and have signed an IRB-approved informed consent in accordance with institutional and federal guidelines.~Exclusion Criteria:~* Serum transaminases \> 1.5 x ULN and direct bilirubin \> 1.5 mg/dl~* HIV positive or active Hepatitis B or Hepatitis C infection; (if serology is positive a quantitative PCR will be done).~* Patients with a prior malignancy in whom life expectancy is more likely to be determined by the prior malignancy than the myeloma. Patients must not currently be receiving therapy for the prior malignancy.~* Pregnant or nursing women. Women of childbearing potential must have a negative pregnancy test documented within one week of registration. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Busulfan (Type: EXPERIMENTAL): study-specific treatment: Busulfex according to study design: Level I 3.2 mg/kg over 6 hours x 2 days Level II 3.2 mg/kg over 6 hours x 3 days Level III 3.2 mg/kg over 6 hours x 4 days Level IV 4.3 mg/kg over 6 hours x 3 days Level V 5.6 mg/kg over 6 hours x 2 days Level VI 6.4 mg/kg over 6 hours x 2 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is able to comprehend and is willing to provide written informed consent and is capable and willing to comply with trial procedures.~2. Patient has completed the IBM4809 trial on treatment with Investigational Medicinal Product (IMP).~Exclusion Criteria:~1. Known or suspected allergy or intolerance to arimoclomol or its constituents.~2. Exposure to any other investigational treatment within 30 days or \<5 half-lives of the baseline visit or taking part or planning to take part in another interventional trial.~3. Significant protocol deviation in the blinded IBM4809 trial based on the investigator's judgement in discussion with the medical monitor.~4. Women who are lactating or pregnant, or men or women unwilling to use a highly effective method of birth control if not surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy for women; vasectomy for men) for female participants until 4 weeks after last dose and for male participants up to 3 months after last dose. Premenopausal women must have a negative pregnancy test prior to dosing with trial medication. Acceptable methods of birth control are:~   * Hormonal methods associated with inhibition of ovulation such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the patient's usual menstrual cycle period) before arimoclomol administration.~  * Total abstinence from sexual intercourse since the last menses before arimoclomol administration. (The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence \[calendar, symptothermal, post-ovulation\] methods are not acceptable methods of contraception).~  * Intrauterine device (IUD) or intrauterine hormone-releasing system (IUS).~5. Any concurrent condition that in the investigator's opinion will significantly interfere with assessment of safety or efficacy.~6. Inability to comply with the protocol-specified procedures/evaluations and scheduled visits as per the investigator.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arimoclomol (Type: EXPERIMENTAL): 248 mg arimoclomol base (equivalent to 400 mg arimoclomol citrate) 3 times daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Prognostic Factors in Aortic Dissection Type B

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years old~* Chronic type B aortic dissection, without surgical treatment~* Medically treated patient~* Medical treatment since more than 1 month and less than 5 years~* Aortic dissection localization : below left subclavian artery and alow femoral artery~* Affiliation to a social security system~* Patient who have given informed consent~Exclusion Criteria:~* History of malignant pathology~* Aortic dissection since less than 1 month or more than 5 years~* Inflammatory or infectious disease of the aorta~* Uncontrolled infectious disease~* Iodine Allergy~* Severe renal insufficiency (cockcroft clearance \<30 mL/min)~* Patient under guardianship or curators~* Any associated medical or psychological condition wich could compromise the patient's ability to participate in the study~* Inability to be submitted to the study follow-up for geographical, social or psychological reasons~* Current pregnancy or lack of effective contraception during their reproductive years~* Suckle

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Relapsed or refractory lymphoma (Grade 1, 2, 3A)~* Received 2 or more prior lines of systemic therapy for lymphoma~* Experienced glucose \>250 mg/dL after copanlisib infusion for treatment of lymphoma~Exclusion Criteria:~* Evidence of histologic transformation~* Follicular Lymphoma Grade 3B~* Active CNS involvement by malignancy~* Elevated AST or ALT \> 5x ULN at Screening~* Unmanageable sensitivity to mammalian-derived drug preparations, or to humanized or human antibodies; managed sensitivities to agents such as obinutuzumab or rituximab or similar agents are not exclusionary~* History of drug or alcohol abuse within the last 6 months~* History or family history of pancreatic neuroendocrine tumors or multiple endocrine neoplasia~* History or family history of pheochromocytoma~* Other gastrointestinal, cardiac, renal and CNS (i.e. hypoglycemia unawareness) conditions specific to diabetes that would pose additional risk to subject's safety or interfere with the study evaluation, procedures or completion in the opinion of the treating physician.~* Female subject is pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REMD-477 (Type: EXPERIMENTAL): REMD-477 (human IgG2 anti-glucagon receptor antibody Volagidemab) will be administered as a subcutaneous injection for three weekly doses

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* With severe non-critical stage of COVID at the time of admission.~* Patients tested positive for SARS-CoV-2 confirmed by PCR (Polymerase Chain Reaction) or quick antigen test~* Within the first 12 days post appearance of symptoms~* With at least one of the following risk factors: Diabetes mellitus (DM), obesity (BMI\>30, hypertension, age \> 65 years.~* Respiratory rate 25-34/min and no signs of respiratory distress.~* With at least two of the following indicators of severity: SpO2 81-90%, PaFi 150-300 mmHg, FiO2\>60% , lung damage in thorax radiographic image =\> 25% as determined by RALE score (an equivalent to 2-4).~* Normal liver function (Considered up to a fivefold increase above the normal limits of hepatic transaminases)~* Signed informed consent~Exclusion Criteria:~* Pregnant or lactating women~* Patients already participating in another clinical study~* Oxygen saturation \< 70% (ambient)~* Clinical evidence of an infectious disease different from COVID at the time of admission~* Chronic kidney failure~* Coronary disease~* Glomerular filtration rate \< 30ml/min/1.73 m2 and known history of preexisting chronic renal failure (Chronic kidney disease stages 4-5)~* Known history of HCV, HBV and/or clinical signs of hepatic liver failure.~* Any type of cancer~* HIV and/or any anti retroviral treatment~* Inability to freely decide to participate~* Psychotropics treatment~* Erythromycin treatment~* Polydrug use (Defined as more than two addictions combined)~* With transplant background~* With any autoimmune disorder~* With known hypersensibility to maraviroc and/or favipiravir~* On invasive mechanical ventilation at the time of randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Currently used therapy (CT) only (Type: ACTIVE_COMPARATOR): Treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients: Enoxaparin, dexamethasone, and antibiotics if associated bacteremia is present.
- Maraviroc+CT (Type: EXPERIMENTAL): Maraviroc AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients.
- Favipiravir+CT (Type: EXPERIMENTAL): Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients.
- Maraviroc+Favipiravir+CT (Type: EXPERIMENTAL): Maraviroc AND Favipiravir AND treatment currently used at Hospital General de México Dr. Eduardo Liceaga for non-critical COVID patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A 48 Subject Study Using Non-invasive Multi-Technology Measurements for Early Detection of Ongoing Hemorrhage

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Adults 18 years or older~2. Patients undergoing liver resection.~3. Ability to give informed consent.~Exclusion Criteria:~1. Pre-existing systemic illness, likely to alter systemic cardiovascular response to hemorrhage. Including congestive heart failure, and a paced cardiac rhythm.~2. Pregnant~3. Prisoner status

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy